Oncology Central

End points in lung cancer clinical trials: are we ready to step away from overall survival?


Overall survival (OS), defined as the time from randomization or registration to death from any cause, is the gold standard end point in clinical trials as it is a measure of direct clinical benefit to a patient. OS as an end point is unambiguous and can unequivocally assess the benefit of a new treatment relative to the current standard of care. While improving OS remains the ultimate goal of new cancer therapy, an intermediate end point, such as progression-free survival (PFS), a composite end point defined as time from randomization to disease progression or death, is commonly used to evaluate the treatment effect of new oncologic products studied in randomized controlled trials (RCTs) [1].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.